Table 2 Adjusted cause-specific Cox proportional hazard regression analyses for time to castration-resistant prostate cancer

From: Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients

Variable

Univariate analysis

Multivariate analysis

 

HR (95% CI)

P-valuea

HR (95% CI)

P-valueb

Age at diagnosis (ref: ≤7; 1 years)

0.667 (0.455–0.979)

0.038

0.722 (0.471–1.107)

0.135

Gleason score at diagnosis (ref: 4≤G≤7)

    

Gleason score ≥8

1.791 (1.189–2.697)

0.005

1.616 (1.065–2.452)

0.024

T stage at diagnosis(ref: ≤T2)

 

<0.001

  

 T3

1.297 (0.624–2.695)

0.486

  

 T4

3.162 (1.622–6.163)

0.001

2.999 (1.406–6.398)

0.004

N stage at diagnosis (ref: N0)

    

 N1

0.982 (0.653–1.478)

0.931

  

M stage at Diagnosis (ref: M0)

    

 M1

1.755 (1.075–2.865)

0.024

0.824 (0.437–1.552)

0.549

Total prostate-specific antigen (ng/ml) (ref: ≤118.78)

1.240 (0.845-1.819)

0.273

  

Free prostate-specific antigen (ng/ml) (ref: ≤19.18)

1.583 (1.074–2.333)

0.02

1.156 (0.76–1.76)

0.498

Free prostate-specific antigen / Total prostate-specific antigen (%)(ref: ≤13.93)

1.240 (0.847–1.814)

0.269

  

Prostate volume (cm3) (ref: ≤106.94)

0.822 (0.560–1.206)

0.316

  

Prostate-specific antigen density (ng/ml/cm3) (ref: ≤1.18)

1.342 (0.917–1.965)

0.130

  

AR-V7 state (ref: negative)

5.571 (3.445–9.007)

<0.001

4.826 (2.960–7.869)

<0.001

  1. aIndividual covariates were tested to predict outcome using a univariate Cox proportional hazards model.
  2. bP-values are the result of a adjusted multivariable Cox proportional hazards model.
  3. Bold values signify the P-value ≤0.05.
Back to article page